期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替莫唑胺治疗难治性垂体腺瘤的研究进展 被引量：1

原文传递
导出
摘要 垂体腺瘤约占颅内肿瘤的10％-25％，人群发病率约为17％，居颅内肿瘤的第二位。除了垂体催乳素（PRL）腺瘤，大部分垂体腺瘤首选手术治疗，但约30％～40％的肿瘤呈侵袭性生长，容易侵犯周围组织，包绕颈内动脉等重要结构，甚至破坏鞍底及斜坡骨质，手术难以全切肿瘤。
作者 代从新 马四海 蔡锋 刘小海 姚勇 王任直
机构地区 中国医学科学院北京协和医院转化医学中心
出处 《中华神经外科杂志》 CSCD 北大核心 2013年第4期423-425,共3页 Chinese Journal of Neurosurgery
关键词 垂体腺瘤 手术治疗 替莫唑胺 难治性 颅内肿瘤 垂体催乳素 侵袭性生长 周围组织
分类号 R736.4 [医药卫生—肿瘤]
  • 相关文献

参考文献34

  • 1Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas : a systematic review. Cancer,2004-, lO1:613-619.
  • 2Colao A, Grasso LF, Pivonello R, et al. Therapy of aggressive pit- uitary tumors. Expert Opin Pharmacother,2011,12 :1561-1570.
  • 3Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pit- uitary adenomas : incidence, clinical characteristics, and implications. J Neurosurg,2011,114 :336-344.
  • 4代从新,蔡锋,刘小海,马四海,姚勇,王任直.难治性垂体腺瘤的治疗现状和展望[J].中华神经外科杂志,2012,28(4):425-427. 被引量：3
  • 5马四海,姚勇,代从新,邓侃,刘小海,蔡锋,李桂林,杨义,马文斌,王任直.替莫唑胺治疗难治性垂体腺瘤一例报告并文献复习[J].中华神经外科杂志,2011,27(5):584-588. 被引量：8
  • 6Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer, 2011, 117: 454-462.
  • 7Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gli- omas: current use and future targets. Caneer Chemother Pharmaeol, 2009,64 : 647 -655.
  • 8Bei R, MarzoeeheUa L, Turriziani M. The use of temozolomide for the treatment of malignant tumors: elinieal evidenee and molecular mechanisms of aetion. Recent Pat Antieancer Drug Discov,2010,5 : 172-187.
  • 9Syro LV, Scheithauer BW, Ortiz LD, et al. Effect of temozolomide in a patient with recurring oncocytie gonadotrophic pituitary adenoma. Hormones (Athens) ,2009,8:303-306.
  • 10Hagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol,2009,161 : 631-637.

二级参考文献49

  • 1Aghi MK. Management of recurrent and refractory Cushing dise- ase. Nat Clin Pract Endocrinol Metab,2008 ,4 :560-568.
  • 2Syro LV,Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer, 2011, 117 : 454-462.
  • 3Fadul CE,Kominsky AI,, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two eases. J Neurosurg ,2006,105:621-626.
  • 4McCormack AI, McDonald KL, Gill AJ, et al. Low O6-methylg- uanine-DNA methyltransferase(MGMT) expression and response to temozolomide in aggressive pituitary turnouts. Clin Endocrinol (Oxf) ,2009,71:226-233.
  • 5Kovacs K, Scheithauer BW, Lombardero M, et al. MGMT imm-unoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol,2008,115:261-262.
  • 6Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas:a French muhicenter experience. J Clin Endocrinol Metab, 2010, 95: 4592-4599.
  • 7Bush ZM, Longtine JA, Cunningham T, et al. Temozolomide trea- tment for aggressive pituitary tumors: correlation of clinical outcome with O ( 6 ) -methylguanine methyltransferase ( MGMT ) promoter methylation and expression. J Clin Endocrinol Metab, 2010,95 : E280-E290.
  • 8Morin E, Berthelet F, Weisnagel J, et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary, 2010. [ Epub ahead of print ].
  • 9Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pit- uitary adenomas: a systematic review. Cancer, 2004, 101:613-619.
  • 10Vance ML. Treatment of patients with a pituitary adenoma: one clinician's experience. Neurosurg Focus ,2004,16 : El.

共引文献9

同被引文献13

  • 1Darnell JE Jr, Kerr IM, Stark GR.Jak-STAT pathways and transcriptional activation in response to IFNs and other extra- cellular signaling proteins [J]. Science, 1994, 264(5164) : 1415-1421.
  • 2Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflamma- tion, and cancer: how intimate is the relationship? [J]. Ann NY Acad Sei, 2009, 1171:59-76.
  • 3Brornberg J. Stat proteins and oncogenesis [ J ]. J Clin In- vest, 2002, 109(9) :1139-1142.
  • 4Yue P, Turkson J. Targeting STAT3 in cancer: how success- ful are we? [J]. Expert Opin Inv Drug, 2009, 18 1): 45-56.
  • 5Wang X, Crowe PJ, Goldstein D, et al. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review) [J]. Int J Oncol, 2012, 41(4) :1181-1191.
  • 6Arzt E. gpl30 eytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways [ J ]. J Clin Invest, 2001, 108 (12) : 1729-1733.
  • 7Mynard V, Guignat L, Devin-Leelerc J, et al. Different mechanisms for leukemia inhibitory factor-dependent activa- tion of two proopiomelanoeortin promoter regions [ J ]. Endo- crinology, 2002, 143(10) :3916-3924.
  • 8Zhou CQ, Jiao YH, Wang RZ, et al. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hyper- secretion [J]. J Clin Invest, 2015, 125(4) :1692-1702.
  • 9Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pi- tuitary adenomas: a systematic review [ J ]. Cancer, 2004, 101:613-619.
  • 10Trovato M, Torre ML, Ragonese M, et al. HGF/c-met sys- tem targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical char- acterization in view of targeted therapies [ J ]. Endocrine, 2013, 44(3) :735-743.

引证文献1

二级引证文献2

中华神经外科杂志
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部